Compound
← Compound
Official website →
JNJJohnson & Johnson
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- JNJ
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-28
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascu…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
31.21×
P/B
Price divided by book value
7.75×
EV/EBITDA
Enterprise value divided by operating cash generation
20.14×
EV/Revenue
Enterprise value divided by revenue
6.94×
What the company earns
ROE
Return on shareholders’ equity
25.7%
ROA
Return on all assets
10.5%
Gross margin
What remains after product costs
67.9%
Operating margin
What remains after operating the business
26.8%
Net margin
How much of each revenue unit becomes profit
21.5%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.58
Total debt
Sum of borrowings
$49.04B
Cash
Cash available to cover it
$20.42B
Current ratio
Short-term assets divided by short-term liabilities
1.09
Free cash flow
Cash left after investing
$3.39B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.24
Dividend yield
Trailing 12-month distributions divided by price
2%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 79.99B | 85.16B | 88.82B | 94.19B |
| Custo dos produtos | -24.6B | -26.55B | -27.47B | -30.26B |
| Lucro bruto | 55.39B | 58.61B | 61.35B | 63.94B |
| Despesas com vendas e administrativas | -20.25B |
News about JNJ
Motley Fool · 12 hours ago
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
The reported transaction is presented as part of J&J’s broader effort to become smaller and more focused after the Kenvue separation. Selling DePuy Synthes could be quicker and cleaner than a spinoff while giving the company cash, but it would also remove a business from the group. The article argues that investors may value the resulting focus, profitability, and growth profile more highly than the benefits of diversification.
Yahoo Finance · 3 days ago
Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
Yahoo Finance · 4 days ago
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
The comparison favors J&J because its long dividend record, cash flow, and diversified business are presented as more dependable than Kenvue's situation amid its proposed acquisition by Kimberly-Clark. The main counterweight is valuation: J&J is described as trading above the sector average, while its legal liabilities remain an unresolved business issue.
Yahoo Finance · 5 days ago
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
Follow JNJ and get agent analysis of what is moving the stock.
Open Compound